We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Daniel Catenacci

Daniel Catenacci MD

Associate Professor of Medicine, The University of Chicago Medicine, Chicago, Illinois

Recent Contributions to PracticeUpdate:

  1. Antibody Drug Conjugates for Gastric Cancer
  2. Margetuximab Along With Retifanlimab in High Expressing HER2+ Gastric Cancer
  3. CAR-T Cell Therapy Against Claudin 18.2 for GI Cancers
  4. Impact of Tumor Neoantigen Vaccine Mediated Specific T-Cell Response Towards Response to Therapy
  5. Adding First-Line Nivolumab to Chemotherapy for Advanced Gastric, GE Junction, and Esophageal Adenocarcinomas
  6. Multimodality Therapy vs Peri-Operative Chemotherapy for Patients With Esophageal/GE Junction Adenocarcinoma
  7. Combination Immunotherapy vs Chemoimmunotherapy for Patients With Advanced Squamous Cell Carcinoma of the Esophagus
  8. Bemarituzumab Plus FOLFOX for Advanced Gastric/GE Junction Adenocarcinoma
  9. FDA Approves Pembrolizumab for Advanced or Metastatic Esophageal/Gastroesophageal Junction Cancer
  10. Ivosidenib for Patients With IDH1-Mutated Cholangiocarcinoma

Most Read This Week

Recently Updated